# An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

> **NCT03167437** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 35 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT03167437
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-30
- **Primary completion:** 2035-06-30
- **Final completion:** 2035-06-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167437, "An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03167437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*